One reason for China’s initially slower vaccine rollout is its success in stopping the virus’ spread. Gao was factually correct: China’s vaccines have a lower efficacy than those produced by Pfizer-BioNTech and Moderna. But there is a possibility that “mixing vaccines” could open the way for use of foreign vaccines in China. But that depends in part on approvals of the Chinese vaccine abroad, the Journal reported. AdvertisementEven China’s lower-efficacy vaccines have proved valuable at preventing serious illness in those who are infected, he said.

Source: Los Angeles Times April 16, 2021 21:23 UTC